Alnylam Starts Liver Cancer Trial
Luke Timmerman 4/3/09
Alnylam Pharmaceuticals (NASDAQ: ALNY), the Cambridge, MA-based developer of RNA interference drug technology, said today it has started an early-phase clinical trial of a treatment for liver cancer. The trial is important because it is Alnylam’s first attempt to make an RNAi drug that can circulate throughout the body, as CEO John Maraganore explained in this interview in December. The trial will enroll 55 patients with liver cancer in the U.S.
Luke Timmerman is the National Biotechnology Editor for Xconomy. You can e-mail him at ltimmerman@xconomy.com, call 206-624-2374, or follow him on Twitter at http://twitter.com/ldtimmerman.
